Recurring Revenue Is King in Landscaping: How Maintenance Contracts Drive Exit Value
Orthopedic Practice Valuation 2026 Data
May 12, 2026
Expert Analysis
Orthopedic Practice Valuation: 2026 Data
The orthopedic practice market remains one of the most active segments in healthcare M&A, with private equity platforms, health systems, and strategic consolidators continuing to pursue scaled, well-positioned groups. Investors are particularly enthusiastic about increasing procedure migration to ambulatory surgery centers.
Healthcare services deal activity increased 9.6% year-over-year in 2025 to approximately 747 transactions, reflecting sustained buyer demand despite broader economic pressure. Orthopedic practices continue to command premium valuations due to procedure-based revenue, high barriers to entry, and favorable demographic tailwinds tied to an aging population.
In 2026, orthopedic practices typically achieve EBITDA multiples of 6–12× depending on size, specialty mix, and ancillary services, with higher valuations for groups that demonstrate multi-physician scale, strong commercial payer mix, and ownership of ancillaries such as ASCs. This report synthesizes current market data to provide clear valuation benchmarks for orthopedic practice owners.
In this article, you’ll learn:
- How orthopedic practice valuations are determined using EBITDA and why most practices trade between 6×–12× multiples in 2026
- What drives higher valuations, including physician scale, ancillary services, and a strong commercial payer mix
- How practice size impacts value, from small add-ons to platform-level groups earning premium multiples
- Why ambulatory surgery center (ASC) ownership can add 1–3 turns to EBITDA multiples and significantly increase overall value
- How buyer demand, physician productivity, and transaction structure shape pricing and deal outcomes in today’s orthopedic M&A market
Actual pricing varies with each transaction based on many factors. Valuations discussed are intended for educational purposes only and are not a guarantee of any outcome. Each transaction is unique.
Orthopedic Practice EBITDA Multiples by Practice Characteristics, 2026
The primary driver of orthopedic practice valuation is adjusted EBITDA, with multiples varying significantly based on practice size, ancillary services, and market positioning. Medical practices generating $5M+ in EBITDA can command 10-12× multiples, while smaller orthopedic groups typically see 6-8× multiples.
| Practice Characteristic | Typical EBITDA Multiple Range | Key Drivers |
|---|---|---|
| Small orthopedic group (<$1M EBITDA, 2-4 physicians) | 4×–7× | Physician-to-physician sales, limited infrastructure |
| Mid-size group ($1M-$3M EBITDA, 5-8 physicians) | 7×–9× | Add-on acquisition for existing platforms |
| Large group ($3M-$7M EBITDA, 9-15 physicians) | 8×–10× | Emerging platform with partial infrastructure |
| Platform group ($7M+ EBITDA, 15+ physicians) | 9×–12× | Established scale, recruiting capability, systems |
| Orthopedic group with owned ASC | +1×–3× additional turns | Procedure margin stability, diversified revenue |
| Pure trauma/call-heavy practice | 6×–8× | Unpredictable scheduling, burnout risk factors |
Sources: Sofer Advisors Medical Practice Valuation Multiples Guide 2025-2026; HealthFMV Ambulatory Surgery Center Valuation Guide 2025
Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
Practices positioned in the upper multiple ranges typically demonstrate diversified physician bench strength, dense geographic coverage, and strong referral networks beyond a single key physician.
Orthopedic Physician Productivity & Compensation Benchmarks, 2026
Orthopedic surgeon productivity directly impacts practice EBITDA and, therefore, valuation. Buyer will adjust current owner compensation to market rates, taking productivity into account. According to MaritHealth’s 2025 physician compensation analysis, orthopedic surgeons generate a median of approximately 10,000 wRVUs annually, with significant variation by subspecialty focus.
| Orthopedic Subspecialty | Median Annual wRVU | Median Compensation | High Producers (90th percentile) |
|---|---|---|---|
| Total Joint Replacement | 9,500-11,000 | $520K-$640K | 14,000-15,000 wRVU |
| Spine Surgery | 10,000-12,000 | $640K-$740K | 15,000+ wRVU |
| Sports Medicine | 7,500-9,500 | $450K-$520K | 12,000+ wRVU |
| Trauma/Fracture Care | 9,000-11,000 | $520K-$600K | 14,000-15,000 wRVU |
| Hand & Upper Extremity | 7,000-9,000 | $420K-$480K | 11,000-12,000 wRVU |
Sources: MaritHealth 2025 wRVUs and Compensation by Specialty Report; RVU Edge MGMA Benchmarks by Specialty; FastRVU Orthopedic Surgery Guide 2026
*wRVU ranges reflect MGMA 2025 DataDive survey data (2024 production year).
Orthopedic surgery compensation typically ranges from $53-57 per wRVU, with a median of $55/wRVU, though geographic location, practice setting, and subspecialty significantly affect rates. According to MaritHealth data, orthopedic surgeons earn a median of $70 per wRVU when including productivity bonuses and facility participation.3 Rural and underserved areas may pay $60+/wRVU for clinical services, while spine surgeons often command $66-70/wRVU premiums due to case complexity.
Buyers evaluating orthopedic practices examine physician-level productivity to assess sustainability beyond current ownership and identify growth potential through recruitment or enhanced operational efficiency. The variation in compensation by subspecialty reflects both procedural complexity and lifestyle factors. Total joint replacement surgeons achieve strong income-to-lifestyle ratios with predictable scheduling and lower call volume, while trauma-focused practices generate higher RVUs but face unpredictable schedules and a higher risk of burnout.
Ambulatory Surgery Center Valuation Impact
Owned ambulatory surgery centers represent the single most significant valuation enhancer for orthopedic practices. ASC EBITDA multiples range from 2.7× to 12.0×, with a median of 10.1×, and ASC ownership can add 1-3 multiple turns to base practice EBITDA valuations, potentially adding value to both entities when sold as a package.2
| ASC Ownership Structure | Potential Valuation Impact | Annual Profit Contribution per Surgeon |
|---|---|---|
| 100% physician-owned orthopedic ASC | +2-3× EBITDA multiple turns | $150K-$250K |
| Joint venture ASC (physician minority stake) | +0.5-1.5× multiple turns | $50K-$120K |
| Management services agreement only | +0.25-0.75× multiple turns; depends on nature of agreement | $30K-$60K |
| Hospital-owned ASC (physician user, no ownership) | Minimal valuation impact | $0 profit share |
Sources: Buckhead FMV Valuator’s View of the ASC Industry in 2026; HealthFMV Ambulatory Surgery Center Valuation Guide 2025; Sofer Advisors Medical Practice Valuation Multiples Guide 2025-2026
*Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
The valuation premium for ASC ownership exists because ancillary services create diversified revenue streams, generate higher margins than standard office visits, and demonstrate operational sophistication that reduces buyer integration risk. Orthopedic practices performing total joint replacements, spine procedures, and sports medicine arthroscopy in owned ASCs capture both the professional fee and facility fee components, with the potential to substantially improve overall EBITDA margins.
According to HealthFMV’s analysis, practices with owned ASCs or other ancillaries achieve revenue diversification that supports 1-3 additional multiple turns beyond base practice valuations. Buyers particularly value orthopedic ASCs positioned to continue migrating cases from hospital outpatient departments as CMS and commercial payers incentivize lower-cost surgical settings. In 2025, Medicare delivered a 2.9% increase to the ASC fee schedule, and CMS has proposed a 2.4% payment rate increase for 2026, along with expansion of the ASC Covered Procedures List by over 500 codes, offering potential volume growth from new procedural opportunities.6
Orthopedic Practice Transaction Size Bands
Practice scale dramatically affects both achievable EBITDA multiples and the composition of the buyer pool. Practices reaching $5M+ in EBITDA often qualify as platforms, and can earn 10-12× multiples compared to 6-8× for smaller add-on acquisitions.2
| Transaction Size | Typical Buyer Profile | Multiple Range | Deal Structure Characteristics |
|---|---|---|---|
| <$10M enterprise value | Physician-to-physician; local group | 4×–6× EBITDA | Asset sale, individual seller rollover |
| $10M-$30M enterprise value | Regional platform; PE add-on | 6×–8× EBITDA | Blend of cash and rollover equity |
| $30M-$50M enterprise value | Established PE platform | 7×–10× EBITDA | Significant cash, 10-20% rollover typical |
| $50M+ enterprise value | National platform; hospital system | 9×–12× EBITDA | Majority cash, structured earnouts available |
Sources: Sofer Advisors Medical Practice Valuation Multiples Guide 2025-2026; PitchBook Q4 2025 Healthcare Services Report
Transaction structure data reflects healthcare M&A market observations. Actual pricing varies with each transaction based on many factors. Intended for educational purposes only and not a guarantee of any outcome.
The scale premium reflects reduced execution risk, greater growth potential, and enhanced attractiveness to institutional buyers. According to PitchBook’s Q4 2025 Healthcare Services Report, physician practice management deal count declined 18% overall in 2025, driven by regulatory friction in certain states and reimbursement uncertainty, though PPM exits jumped 57.1%, signaling that transaction volume could recover in 2026. Orthopedic and musculoskeletal practices were specifically identified as recovery sectors for 2026 M&A activity.
Orthopedic groups positioned in the $30M-$50M enterprise value range typically access the most competitive buyer processes, with multiple private equity platforms, management services organizations, and hospital systems competing simultaneously. Smaller orthopedic practices with an enterprise value below $10M often transact as add-ons to existing platforms or through physician-to-physician succession arrangements. While these transactions can close successfully, they typically command lower multiples due to key person dependency, limited infrastructure, and integration requirements for platform buyers.
<!– ============================================================
BLADE 03: STICKY SIDEBAR / BOTTOM BAR
Copy EVERYTHING from here ↓ (including the small block)
Behavior:
– Desktop (≥ 1024px): floats as a sidebar widget on the right
– Mobile (
Requesting Information About Orthopedic Practice Valuation
FOCUS Investment Banking specializes in maximizing transaction value for healthcare practice owners through proven M&A advisory services. Our team has completed more than 130 healthcare transactions since 2016, including extensive experience with medical practice and ASC sales.
If you’d like to learn more about the valuation of orthopedic practices or discuss your specific situation, contact our team.
Sources:
- PitchBook (February 2026) — Q4 2025 Healthcare Services Report
- Sofer Advisors (2025) — Medical Practice Valuation Multiples 2025-2026: Complete Guide
- MaritHealth (2025) — 2025 wRVUs and $ per wRVU by Specialty: A Guide for Physicians
- FastRVU (2026) — Orthopedic Surgery RVU Guide 2026 | MGMA 2025 Benchmarks
- Buckhead Fair Market Value (2026) — A Valuator’s View of the ASC Industry in 2026
- HealthFMV (2025) — Valuing Ambulatory Surgery Centers in 2025: A Comprehensive Guide Available
- RVU Edge (2025) — MGMA Benchmarks by Specialty
Written by
Eric Yetter
Managing Director
Eric Yetter is an investment banker focused on healthcare provider services. Eric has completed a variety of healthcare transactions, many with private equity firms and PE-backed companies. His past clients include leading physician and dental groups, behavioral health companies, healthcare facilities, and institutional healthcare investors.
View Bio
Written by
Managing Director
Related Insights
Let's connect
M&A guidance, backed by real experience
Whether you’re exploring a sale, raising capital, or simply want an outside perspective on where your business stands, our bankers are ready to listen. Reach out to start a confidential conversation with the FOCUS team.
